Daniel J Drucker

GLP-1 medicines have multiple direct and indirect effects that modify cardiovascular risk. Here Kyle Medak @SinaiHealth and colleagues identify an important role for the VSM GLP-1R in the reduction of blood pressure #hypertension @JCI_insight @uoftmedicine insight.jci.org/articles/view/…

GLP-1 medicines and #pancreatitis After 21 years, lots of smoke, no fire. Here a look at Tirzepatide sciencedirect.com/science/articl…

Here the authors propose repurposing readily accessible DPP-4 inhibitors to enhance anti-tumor CD8+ T cell responses #cancer biorxiv.org/content/10.648…

Associations in humans suggest that Hyperglucagonemia in the face of higher hepatic lipid content in early #T2D is not due to differences in insulin sensitivity or glucagonotropic metabolites but could suggest hepatic glucagon resistance diabetesjournals.org/care/article/d…

Novel irisin-driven cell–cell and inter-tissue immune interactions improve #obesity and glucose intolerance, and increase energy expenditure, with no reduced food intake and muscle loss in obese mice. nature.com/articles/s4225…

Studies of mouse adipose tissue biology continue to underpin the enthusiastic pursuit of new targets to enhance thermogenesis in humans nature.com/articles/s4146…

The epidemiology of GLP-1 medicines-suggestive protective associations with reduced rates of respiratory diseases and serious infections require further confirmation jamanetwork.com/journals/jaman…

Preclinical studies define potential strategies against hepatic insulin resistance by targeting sulfenylated or ‘oxidatively activated’ p-GSK-3β. nature.com/articles/s4225…

Prespecified analyses reveal semaglutide reduced MACE in patients at risk for substantial liver fibrosis, in the overall SELECT population nature.com/articles/s4159…

Using the new voucher system, orforglipron represents the fastest approval of a New Molecular Entity (NME) @US_FDA since 2002.fda.gov/news-events/pr…

Important new #weightloss option for people with overweight and #obesity Orforglipron, the first @US_FDA approved small molecule GLP-1 medicine. Innovation from Chugai and Eli Lilly investor.lilly.com/news-releases/…

Systemic DPP-4 inhibition is not cardioprotective in humans however microbial-derived DPP4 exacerbates cardiac I/R injury highlighting the hypoxia-lactate-BaDPP4 axis as a promising target for #microbiota-based cardioprotection cell.com/cell-host-micr…

Here surface-anchored Adpn EVs restore tissue-specific insulin signaling and improve obesity-related metabolic dysfunctions, highlighting their potential as a novel biotherapeutic strategy for #T2D and #MASH sciencedirect.com/science/articl… @MolMetab

The 2026 Canada @GairdnerAwards Laureates from Cryo-EM to amyloid aggregation,systems proteomics, cholera control, bacterial immunity, BP control after spinalinjury #Science newswire.ca/news-releases/…

A continuous intravenous LEAP2 infusion for 5 hrs reduces glycemia and food intake in men with #obesity diabetesjournals.org/diabetes/artic…

While waiting for FOCUS, analysis of a matched real world TriNetX cohort of 350,536 patients with #T2D and #CVD followed for up to 5 years revealed reduced rates of legal blindness pubmed.ncbi.nlm.nih.gov/41907810/

Another win for the lower is better crowd… Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease | New England Journal of Medicine nejm.org/doi/full/10.10…

As the weight loss-independent actions of GLP-1 medicines unfold a greater reduction in PsA disease activity (ACR50) was seen as early as Week 4 in the Ixekizumab and Tirzepatide treatment arm before clinically meaningful weight loss was observed investor.lilly.com/news-releases/…

The journey towards therapeutic manipulation of energy expenditure for #weightloss cell.com/trends/endocri…

Studies in mice identify a septal inhibitory circuit through which GLP-1R signaling modulates alcohol-related behaviors in mice and highlight the dLS as a therapeutic target for Alcoholism Use Disorders cell.com/neuron/abstrac…